Haematology 2018

Designing a clinical trial of RT + checkpoint blockade for relapsed and refractory FL

Hypothesis

Low-dose RT plus anti-PD-L1 Ab (atezolizumab) is safe and able to improve systemic responses compared to atezolizumab alone